LLY

1,066.57

-0.02%↓

JNJ

230.23

-1.85%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

AZN

187.14

-0.06%↓

LLY

1,066.57

-0.02%↓

JNJ

230.23

-1.85%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

AZN

187.14

-0.06%↓

LLY

1,066.57

-0.02%↓

JNJ

230.23

-1.85%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

AZN

187.14

-0.06%↓

LLY

1,066.57

-0.02%↓

JNJ

230.23

-1.85%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

AZN

187.14

-0.06%↓

LLY

1,066.57

-0.02%↓

JNJ

230.23

-1.85%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

AZN

187.14

-0.06%↓

Home・Elenco Azioni・Erasca Inc

Erasca Inc

Chiusa

11.48 2.23

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

10.99

Massimo

11.57

Metriche Chiave
By Trading Economics
Entrata	-154M -183M
EPS	-0.6
Dipendenti	103
EBITDA	-5.3M -37M

Raccomandazioni
By TipRanks
Raccomandazioni	Acquista
Previsioni per 12 mesi	+80.34% upside

Dividendi
By Dow Jones
Utili prossimi	10 ago 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	249M 3.5B
Apertura precedente	9.25
Chiusura precedente	11.48

Erasca Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

26 mag 2026, 16:52 UTC

Principali Notizie su Eventi

NYMEX Overview: Brent Crude Futures Up; Iran Warns of Retaliation After US Strike -- OPIS

26 mag 2026, 23:57 UTC

Utili

Sociedad Quimica 1Q Rev $1.76B >SQM

26 mag 2026, 23:57 UTC

Utili

Sociedad Quimica 1Q EPS $1.28 >SQM

26 mag 2026, 23:48 UTC

Discorsi di Mercato

Nikkei May Rise on Continued AI Enthusiasm -- Market Talk

26 mag 2026, 21:54 UTC

Utili

Webco Industries 3Q EPS $11.61 >WEBC

26 mag 2026, 21:54 UTC

Utili

Webco Industries 3Q Sales $179.6M >WEBC

26 mag 2026, 21:48 UTC

Discorsi di Mercato

GE Aerospace's Repair Boom Should Last for Years -- Market Talk

26 mag 2026, 21:00 UTC

Discorsi di Mercato

ESG Roundup: Market Talk

26 mag 2026, 20:58 UTC

Acquisizioni, Fusioni, Takeovers

Uber's $11.6 Billion Bid for DoorDash Rival Is About Future Proofing It From Robots -- Barrons.com

26 mag 2026, 20:50 UTC

Discorsi di Mercato

Tech, Media & Telecom Roundup: Market Talk

26 mag 2026, 20:50 UTC

Discorsi di Mercato

Auto & Transport Roundup: Market Talk

26 mag 2026, 20:50 UTC

Discorsi di Mercato

Financial Services Roundup: Market Talk

26 mag 2026, 19:22 UTC

Discorsi di Mercato

Cryptocurrencies Add to Losses in Afternoon Trading -- Market Talk

26 mag 2026, 19:17 UTC

Discorsi di Mercato

Oil Recovers Some Losses on U.S.-Iran Skirmishes -- Market Talk

26 mag 2026, 18:56 UTC

Discorsi di Mercato

U.S. Natural Gas Futures Slip in Rangebound Trading -- Market Talk

26 mag 2026, 18:03 UTC

Discorsi di Mercato

AutoCanada Faces Soft Demand, Slow Normalization -- Market Talk

26 mag 2026, 17:42 UTC

Discorsi di Mercato

Grains Await Fresh Trading Catalyst -- Market Talk

26 mag 2026, 17:33 UTC

Discorsi di Mercato

Salesforce, Snowflake Could Dispel Software Bear Thesis -- Market Talk

26 mag 2026, 17:21 UTC

Discorsi di Mercato

Canada Faces a Labor Market Squeeze -- Market Talk

26 mag 2026, 16:52 UTC

Discorsi di Mercato

Bonds to Fund Infrastructure for Data Centers Could Be Risky -- Market Talk

26 mag 2026, 16:43 UTC

Discorsi di Mercato

Spotify's Latest Audio Play: Magazine Articles -- Market Talk

26 mag 2026, 16:24 UTC

Discorsi di Mercato

Dollarama's LATAM Slowdown, Australia Costs Seen as Transient -- Market Talk

26 mag 2026, 16:21 UTC

Discorsi di Mercato

Oil Extends Gains As Strikes Add Tension to U.S.-Iran Talks -- Market Talk

26 mag 2026, 16:20 UTC

Discorsi di Mercato

Tech, Media & Telecom Roundup: Market Talk

26 mag 2026, 16:20 UTC

Discorsi di Mercato

Energy & Utilities Roundup: Market Talk

26 mag 2026, 16:20 UTC

Discorsi di Mercato

Financial Services Roundup: Market Talk

26 mag 2026, 16:20 UTC

Discorsi di Mercato

Acquisizioni, Fusioni, Takeovers

Auto & Transport Roundup: Market Talk

26 mag 2026, 16:16 UTC

Discorsi di Mercato

Alberta Separation Threat Poses Headwind for Canada Dollar -- Market Talk

26 mag 2026, 16:01 UTC

Discorsi di Mercato

Bitcoin Lower as Stress Builds for Holders -- Market Talk

26 mag 2026, 15:21 UTC

Discorsi di Mercato

Hyperliquid Pushes Up to New All-Time High -- Market Talk

Confronto tra pari

Modifica del prezzo

Erasca Inc Previsione

Obiettivo di Prezzo

By TipRanks

80.34% in crescita

Previsioni per 12 mesi

Media 20.27 USD 80.34%

Alto 30 USD

Basso 9 USD

Basato su 11 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Erasca Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

11 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 11 che hanno fornito valutazioni azionarie a Erasca Inc - Dist negli ultimi 3 mesi.

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Erasca Inc

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.